Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited (ASX:IMU) for $6 million on April 16, 2024. Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 AUD | +7.14% | -8.54% | -31.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.82% | 362M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.